Mesoblast (OTCMKTS:MEOBF) Stock Passes Above 200 Day Moving Average – What’s Next?

Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.64 and traded as high as $1.65. Mesoblast shares last traded at $1.65, with a volume of 1,000,250 shares.

Mesoblast Stock Performance

The stock has a fifty day moving average price of $1.68 and a 200 day moving average price of $1.64.

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.

The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.

Featured Articles

• Five stocks we like better than Mesoblast
• Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
• Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
• Can Tesla’s Flying Roadster Distract From Its Real Risks?
• Photronics Is Quietly Becoming a Key Winner From the AI Boom